共 146 条
[1]
Schiffmann R(2015)Fabry disease Handb Clin Neurol 132 231-248
[2]
Arends M(2017)Characterization of classical and nonclassical Fabry disease: A multicenter study J Am Soc Nephrol 28 1631-1641
[3]
Wanner C(2019)Enzyme replacement therapy clears Gb3 deposits from a podocyte cell culture model of Fabry disease but fails to restore altered cellular signaling Cell Physiol Biochem 52 1139-1150
[4]
Hughes D(2001)Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease N Engl J Med 345 9-16
[5]
Mehta A(2002)Globotriaosylceramide accumulation in the Fabry kidney is cleared from multiple cell types after enzyme replacement therapy Kidney Int 62 1933-1946
[6]
Oder D(2007)Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease J Am Soc Nephrol 18 1547-1557
[7]
Watkinson OT(2017)Retrospective study of long-term outcomes of enzyme replacement therapy in Fabry disease: analysis of prognostic factors PLoS One 12 351-358
[8]
Braun F(2018)Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study J Med Genet 55 162-168
[9]
Blomberg L(2019)Antibodies against recombinant alpha-galactosidase A in Fabry disease: subclass analysis and impact on response to treatment Mol Genet Metab 126 2879-2889
[10]
Brodesser S(2018)Dose-dependent effect of enzyme replacement therapy on neutralizing antidrug antibody titers and clinical outcome in patients with Fabry disease J Am Soc Nephrol 29 534-544